Introduction {#Sec1}
============

There are three turkey β-adrenoceptors (Baker [@CR5]). The first one described, commonly simply referred to as the turkey β-adrenoceptor (Bilezikian and Aurbach [@CR10], [@CR11]; Schramm et al. [@CR23]), is a Gs-coupled G protein-coupled receptor (GPCR) that has recently been crystallised and its structure determined to 2.7 Å resolution (Warne et al. [@CR29]). Crystallisation required milligramme quantities of pure, homogenous receptor, in a single conformation, that was stable in detergent (Warne et al. [@CR30]). The native turkey β-adrenoceptor, which is significantly more stable than the human β~1~ adrenoceptor (Serrano-Vega and Tate [@CR25]), was still too unstable in short chain detergents for crystallisation and it also contained flexible regions that would prevent the formation of well-diffracting crystals. Therefore, the receptor was modified in a series of stages to increase both its stability and to also reduce the amount of unstructured regions.

Initially, part of the very large C-terminus was deleted and a C116L mutation made to make the starting construct: tβtrunc construct (Baker [@CR5]; Warne et al. [@CR29]). Deletion of the N-terminus, made the β6 construct, which significantly increased heterologous expression in the baculovirus expression systems (Warne et al. [@CR28]). This β6 construct was then modified, firstly by introducing 6-point mutations to increase the thermostability (the m23 mutations; Serrano-Vega et al. [@CR24], Fig. [1b](#Fig1){ref-type="fig"}) and secondly residues in intracellular loop three, C-terminus and the palmitoylation site were removed (β36 deletions; Warne et al. [@CR30], Fig. [1c](#Fig1){ref-type="fig"}). Combination of the receptor truncations (β36 deletions) and the thermostabilising mutations (m23 mutations) to form the construct β36--m23 (Fig. [1d](#Fig1){ref-type="fig"}) allowed crystallisation and structure determination (Warne et al. [@CR29], [@CR30]). Fig. 1The amino acid sequence of the turkey β-adrenoceptor after deletion of the C-terminal 50 amino acid residues (tβtrunc) and the three other mutants, β6--m23, β36 and β36--m23 used in this study. Thermostabilising point mutations are coloured *blue*, the original C116L mutation in *yellow* and the C358A mutation to remove the palmitoylation sites in *orange*

The turkey β-adrenoceptor has several characteristics similar to that of the human β~1~-adrenoceptor. If the amino acid sequences are compared, there is 82% identity between the transmembrane regions of both receptors with all the residues essential for catecholamine binding being absolutely conserved (Warne et al. [@CR29]). Certain pharmacological characteristics are also very similar between the two receptors. For example, CGP12177 is an agonist at both receptors and its responses are similarly resistant to inhibition by classical antagonists (Baker [@CR3]; [@CR5]; Konkar et al. [@CR20]; Lowe et al. [@CR21]). In addition, both receptors show a significant difference between their affinity (*K*~*D*~ value) for CGP12177 and its partial agonist EC~50~ value in functional assays (Baker et al. [@CR7], Baker [@CR5]; Konkar et al. [@CR20]). Furthermore, several ligands appear to stimulate a two-component concentration response curve in both receptors, suggesting that they appear to exist in at least two agonist-induced conformations (Arch [@CR1]; Baker et al. [@CR7], [@CR5], [@CR6]; Molenaar [@CR22]; Walter et al. [@CR27]). There are, however, a few notable differences between the receptors, for example the affinity of CGP20712A (a human β~1~-selective adrenoceptor antagonist) and ICI118551 (a human β~2~-selective antagonist) are similar at the turkey β-adrenoceptor (tβtrunc).

Structural information on GPCRs is very helpful in the field of drug discovery and GPCR structures will potentially assist in computer-aided drug design (Congreve and Marshall [@CR13]). However, the mutations introduced into the native receptor that were essential for structure determination may cause alterations to the receptor pharmacology. Therefore, for the maximum benefit to be realised from the structure, it is essential to understand the effects of the mutations on the pharmacological characteristics of the receptor. Here, we examine in detail the pharmacological effects of both the m23 mutations and the β36 deletions, both alone and in combination in the β36--m23 mutant used in the crystallisation and structure determination of the turkey β-adrenoceptor (Warne et al. [@CR29]). This study looks at the binding characteristics of both agonists and antagonists to assess affinity changes, functional assays to examine receptor ligand efficacy and an analysis of the two agonist conformations observed for some ligands.

Methods {#Sec2}
=======

Materials {#Sec3}
---------

Foetal calf serum which was from PAA Laboratories (Teddington, Middlesex, UK). Microscint 20 scintillation fluid from PerkinElmer (Shelton, CT, USA). ^3^H-CGP12177, ^3^H-adenine and ^14^C-cAMP were from Amersham International (Buckinghamshire, UK). Betaxolol, bisoprolol, bucindolol, BRL37344, carvedilol, cimaterol, formoterol, ICI 215001, isoprenaline, L755507, salmeterol, SDZ21009, SR59230A, ZD2079 and ZD7114 were from Tocris Life Sciences (Avonmouth, UK). Carazolol was from US Biological (Swampscott, MA, USA) nebivolol and butoxamine were a gift from Stefano Evangelista (Menarini Ricerche Spa, Florence, Italy); zinterol was a gift from Dr. Torsten Christ (Department of Pharmacology and Toxicology, Dresden University of Technology, Germany.). All other reagents were from Sigma Chemicals (Poole, Dorset, UK).

Constructs, cell lines and cell culture {#Sec4}
---------------------------------------

As the full-length turkey β-adrenoceptor did not express (Baker [@CR5]), the starting point for this study (tβtrunc) was a C-terminally truncated version of the turkey β-adrenoceptor that has 59 amino acids deleted from the C-terminus (residues 425--483) and one-point mutation C116L (Fig. [1a](#Fig1){ref-type="fig"}; Warne et al. [@CR29]). This improved functional expression of the turkey β-adrenoceptor by threefold in the baculovirus expression system. In order to improve expression of the receptor for structural studies, 30 amino acid were deleted from the N-terminus (residues 2--32; construct β6; Warne et al. [@CR28]). The thermostability of the receptor was increased by the inclusion of 6 point mutations introduced into the receptor (R67S, M90V, Y227A, A282L, F327A, F338M), which are referred to as the m23 mutations (construct = β6--m23; Serrano-Vega et al. [@CR24]). This increased the thermostability of the receptor and its tolerance to short-chain detergents by increasing kinetic barriers to the unfolded state (Balaraman et al. [@CR9]; Serrano-Vega et al. [@CR24]). The second round of changes involved removing potentially disordered flexible regions from the intracellular portion of the receptor. As well as the 30 amino acid deletion from the N-terminus (β6 construct), 30 amino acids were also deleted from the third intracellular loop (residues 244--271 and 277--278), a further 56 amino acids deleted from the C-terminus (residues 369--424) and a point mutation C358A introduced to remove the palmitoylation site (Warne et al. [@CR30]). These are known as the β36 deletions (construct = β36; Warne et al. [@CR30]). Both of these sets of changes were then combined into the final product (β36--m23) from which the X-ray crystal structure was determined (Fig. [1](#Fig1){ref-type="fig"}; Warne et al. [@CR29], [@CR30]). Each of these constructs were then transfected into a Chinese hamster ovary K1 cells (CHO-K1) cell line stably expressing a six cAMP response element -- secreted placental alkaline phosphatise reporter (CRE-SPAP) reporter gene using Lipofectamine and OPTIMEM as per manufacturer's instructions and a stable cell line of each mutation made by dilution cloning.

In order to check that there were no significant changes in the pharmacology of the receptor during the generation of the stable cell lines, CHO-K1 cells were also transiently transfected with each receptor construct and the binding of ligands examined under transient conditions (initial binding experiments only, see "[Results](#Sec12){ref-type="sec"}" section). Here, the parent CHO-SPAP cells were transfected on day 1, the transfection reagents removed and replaced with media on day 2, the cells plated in to white-sided 96-well plates on day 3 and a binding assay performed on day 4.

All cell lines were grown in Dulbecco's modified Eagle's medium nutrient mix F12 containing 10% foetal calf serum and 2 mM [l]{.smallcaps}-glutamine in a 37°C humidified 5% CO~2~: 95% air atmosphere.

^3^H-CGP12177 whole cell binding {#Sec5}
--------------------------------

Cells were grown to confluence in white-sided tissue culture treated 96-well view plates. ^3^H-CGP12177 whole cell competition binding was performed as previously described (Baker [@CR4]) using ^3^H-CGP12177 in the range of 0.932--3.030 nM (total volume 200 μl per well). For saturation experiments, concentrations of ^3^H-CGP12177 in the range of 0.004--50.41 nM were used. The receptor expression level of the β6--m23 line was significantly higher than the other three cell lines, thus potentially posing a problem of ligand depletion. The total well volume to surface area of cells was therefore increased by carrying out an identical method, across all four cell lines, in 24-well plates (total volume of 2 ml per well) and 48-well plates (total volume per well of 1.6 ml). For each individual cell line, the different methods yielded similar *K*~*D*~ values ^3^H-CGP 12177, suggesting that ligand depletion was not a major factor. The results presented are therefore the mean ± SEM of the results from whole cell binding carried out in 24-, 48- and 96-well plates.

CRE-SPAP production {#Sec6}
-------------------

Cells were grown to confluence in clear plastic tissue culture treated 96-well plates and CRE-SPAP secretion into the media measured between 5 and 6 h after the addition of agonist as previously described (Baker [@CR5]).

^3^H-cAMP accumulation {#Sec7}
----------------------

Cells were grown to confluence in clear plastic tissue culture treated 24-well plates. Following ^3^H-adenine pre-labelling, ^3^H-cAMP accumulation in the wells was measured as previously described (Baker [@CR5]). ^3^H-cAMP was separated from other ^3^H-nucleotides by sequential Dowex and alumina column chromatography as previously described (Donaldson et al. [@CR14]).

Data analysis {#Sec8}
=============

Whole cell binding--saturation binding {#Sec9}
--------------------------------------

Saturation binding curves of the total and nonspecific binding (as determined by the presence of 10 μM propranolol) were performed in order to determine the specific binding *K*~*D*~ value for ^3^H-CGP12177 and the receptor expression level. All data points on each binding curve were performed in quadruplicate. Specific binding (SB, Eq. [1](#Equ1){ref-type=""}) of ^3^H-CGP12177 at different concentrations of ^3^H-CGP 12177 was fitted using the nonlinear regression programme Prism 2.01 to the equation: $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {\text{SB}} = \frac{{\left( {A \times {B_{\text{MAX}}}} \right)}}{{\left( {A + {K_D}} \right)}} $$\end{document}$$where, *A* is the concentration of ^3^H-CGP12177, *B*~MAX~ is the maximal specific binding and *K*~*D*~ is the dissociation constant of ^3^H-CGP12177. Protein was determined by using a Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, USA) as per manufacturers' instructions.

Whole cell binding--competition binding {#Sec10}
---------------------------------------

All data points on each binding curve were performed in triplicate and each 96-well plate also contained six determinations of total and nonspecific binding. In all cases where a *K*~*D*~ value is stated, the competing ligand completely inhibited the specific binding of ^3^H-CGP12177.

A one-site sigmoidal response curve was then fitted to the data using Graphpad Prism 2.01 and the IC~50~ was then determined as the concentration required to inhibit 50% of the specific binding. $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \% \,{\text{of uninhibited}}\,{\text{binding}} = 100 - \frac{{\left( {100\, \times \,A} \right)}}{{A + {\text{I}}{{\text{C}}_{50}}}} + {\text{NS}} $$\end{document}$$where, *A* in the concentration of the competing ligand, IC~50~ is the concentration at which half of the specific binding of ^3^H-CGP12177 has been inhibited and NS is the nonspecific binding.

From the IC~50~ value and the known concentration of ^3^H-CGP12177, a *K*~*D*~ value (concentration at which half the receptors are bound by the competing ligand) was calculated using the equation: $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {K_D} = \frac{{I{C_{50}}}}{{1 + \left( {\left[ {^3H - CGP12177} \right]/{K_D}^3H - CGP12177} \right)}} $$\end{document}$$

Functional assays---^3^H-cAMP accumulation and CRE-SPAP production {#Sec11}
------------------------------------------------------------------

Most agonist responses were best described by a one-site sigmoidal concentration response curve (Eq. [4](#Equ4){ref-type=""}) $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {\text{Response}} = \frac{{{E_{\text{MAX}}} \times \left[ A \right]}}{{{\text{E}}{{\text{C}}_{50}} + \left[ A \right]}} $$\end{document}$$

Where *E*~MAX~ is the maximum response, \[*A*\] is the agonist concentration and EC~50~ is the concentration of agonist that produces 50% of the maximal response

The affinity of antagonists was calculated (*K*~*D*~ values) from the shift of the agonist concentration responses in the presence of a fixed concentration of antagonist using Eq. [5](#Equ5){ref-type=""}: $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {\text{DR}} = 1 + \frac{{\left[ B \right]}}{{{K_D}}} $$\end{document}$$where, dose ratio (DR) is the ratio of the agonist concentration required to stimulate an identical response in the presence and absence of a fixed concentration of antagonist \[*B*\].

In experiments where three different fixed concentrations of the same antagonist were used, Schild plots were constructed using the following Eq. [6](#Equ6){ref-type=""}: $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
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                \usepackage{amsfonts} 
                \usepackage{amssymb} 
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                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \log \left( {{\text{DR}} - 1} \right) = \log \left[ B \right] - \log \left( {{K_D}} \right) $$\end{document}$$

These points were then fitted to a straight line. A slope of 1 then indicates competitive antagonism (Arunlakshana and Schild [@CR2]).

When CGP 12177 was used to antagonise the more efficacious agonists where clear partial agonism was seen, the affinity was calculated by the method of Stephenson ([@CR26]) using Eq. [7](#Equ7){ref-type=""}: $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {K_D}\,{\text{partial agonist}} = \frac{{Y \times \left[ P \right]}}{{1 - Y}}\,{\text{where}}\,Y = \frac{{\left[ {{A_2}} \right] - \left[ {{A_1}} \right]}}{{{A_3}}} $$\end{document}$$where \[*P*\] in the concentration of CGP12177, \[*A*~1~\] in the concentration of the agonist at the point where CGP12177 alone causes the same response, \[*A*~2~\] is the concentration of agonist causing a given response above that achieved by CGP12177 and \[*A*~3~\] the concentration of the agonist, in the presence CGP12177, causing the same stimulation as \[*A*~2~\].

Several of the responses were however best fitted to a two-site concentration response---Eq. [8](#Equ8){ref-type=""} (e.g. Fig. [9](#Fig9){ref-type="fig"}). $$\documentclass[12pt]{minimal}
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                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \% \,{\text{maximal}}\,\,{\text{stimulation}} = \frac{{\left[ A \right] \times N}}{{\left( {\left[ A \right] + {\text{EC}}{1_{50}}} \right)}} + \frac{{\left[ A \right] \times \left( {100 - N} \right)}}{{\left( {\left[ A \right] + {\text{EC}}{2_{50}}} \right)}} $$\end{document}$$where *N* is the percentage of site 1, \[*A*\] is the concentration of agonist and EC1~50~ and EC2~50~ are the respective EC~50~ values for the two agonist sites.

A two-site analysis was also used for experiments, e.g. Fig. [10](#Fig10){ref-type="fig"} using Eq. [9](#Equ9){ref-type=""}: $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {\text{Response}} = {\text{Basal}} + \left( {{\text{Ag - Basal}}} \right)\left( {1 - \frac{{\left[ P \right]}}{{\left( {\left[ P \right] + {\text{I}}{{\text{C}}_{50}}} \right)}}} \right) + {\text{PA}}g\left( {\frac{{\left[ P \right]}}{{\left( {\left[ P \right] + {\text{E}}{{\text{C}}_{50}}} \right)}}} \right) $$\end{document}$$where basal is the response in the absence of agonist, Ag is the response to a fixed concentration of agonist, \[*P*\] is the concentration of CGP12177, IC~50~ is the concentration of CGP12177 that inhibits 50% of the response of the fixed agonist, PAg is the maximum stimulation by the CGP12177 and EC~50~ is the concentration of competing agonist that stimulated a half maximal CGP12177 response.

A 10 μM (maximal) isoprenaline concentration was included in two to three wells in each plate for each separate experiment for ^3^H-cAMP accumulation and six wells of each plate for CRE-SPAP production and, to allow agonist responses to be expressed as a percentage of the isoprenaline maximum for each experiment. All data are presented as mean ± SEM of triplicate determinations (except saturation binding experiments where determinations were from quadruplicate wells) and *n* in the text refers to the number of separate experiments.

Results {#Sec12}
=======

Ligand affinity---^3^H-CGP12177 whole cell binding {#Sec13}
--------------------------------------------------

Binding studies were performed on both transiently transfected cells and the stable cell lines to ensure that the stable cell lines were indeed a true reflection of the pharmacology of the transfected receptors and that no alteration of the receptor pharmacology had taken place during the process of making the cell line. The results from eight separate transiently transfected cell populations (both *K*~*D*~ of ^3^H-CGP12177 from saturation studies and *K*~*D*~ values of betaxolol, bisoprolol, clenbuterol, CGP20712A, formoterol, ICI118551, metoprolol and xamoterol from competition studies) showed a similar pattern of log *K*~*D*~ values to those obtained from the stable cell line (Baker et al. [@CR8]), so only the stable cell line data are presented here.

^3^H-CGP12177 bound specifically to all four turkey β-adrenoceptors mutants to give *K*~*D*~ values (from all 96-, 48- and 24-well plate methods combined) of 0.32 ± 0.02 nM (*n* = 28) for the tβtrunc (receptor expression level of 148 fmol/mg protein; Baker [@CR5]), 0.85 ± 0.09 nM (*n* = 27) for the β6--m23 (2,785 fmol/mg protein), 0.34 ± 0.02 nM (*n* = 26) for the β36 (134 fmol/mg protein) and 0.88 ± 0.08 nM (*n* = 28) for the β36--m23 (254 fmol/mg protein) in the stable cell lines generated. The value presented in Baker ([@CR5]) for the tβtrunc receptor of 0.42 nM is from the 96-well plate method alone. The affinity of a range of other ligands (including agonists, partial agonists and neutral agonists, see below) was then assessed (Table [1](#Tab1){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). Table 1Log *K*~*D*~ values obtained from ^3^H-CGP12177 whole cell binding studies in CHO cells stably expressing either the tβtrunc, β36, β6--m23 or β36--m23 adrenoceptorstβtrunc^a^β6--m23*n*β36*n*β36--m23*n*Acebutolol−5.85−4.91 ± 0.055−5.81 ± 0.066−4.72 ± 0.077Adrenaline−6.01−3.81 ± 0.0711−5.88 ± 0.047−3.88 ± 0.086Alprenolol−7.96−7.40 ± 0.055−8.09 ± 0.025−7.35 ± 0.077Atenolol−5.40−4.57 ± 0.055−5.23 ± 0.036−4.29 ± 0.116Betaxalol−6.90−6.38 ± 0.015−6.53 ± 0.046−5.85 ± 0.076BRL35135A−6.32−5.37 ± 0.105−6.86 ± 0.115−6.00 ± 0.105BRL37344−5.19−4.03 ± 0.075−5.25 ± 0.076−4.27 ± 0.046Bisoprolol−6.70−5.66 ± 0.055−6.37 ± 0.056−5.38 ± 0.046Bupranolol−8.43−7.78 ± 0.045−8.42 ± 0.056−7.61 ± 0.086Bucindolol−9.43−8.71 ± 0.024−9.39 ± 0.076−8.56 ± 0.086Butoxamine−5.24−4.93 ± 0.075−5.22 ± 0.066−4.78 ± 0.105Carazolol−10.20−9.09 ± 0.0413−10.08 ± 0.056−9.23 ± 0.106Carvedilol−9.43−8.69 ± 0.075−9.58 ± 0.065−8.72 ± 0.095CGP20712A−7.53−6.59 ± 0.0511−7.47 ± 0.078−6.38 ± 0.098Cimaterol−7.17−5.44 ± 0.048−7.33 ± 0.069−5.56 ± 0.069CL316243≥4≥44≥46≥46Clenbuterol−6.74−5.56 ± 0.025−6.89 ± 0.066−5.66 ± 0.056S-Cyanopindolol−10.89−9.85 ± 0.0712−10.81 ± 0.076−10.01 ± 0.116Denopamine−6.29−5.13 ± 0.047−6.29 ± 0.057−4.99 ± 0.066Dobutamine−5.69−5.40 ± 0.015−5.74 ± 0.066−5.49 ± 0.036Fenoterol−6.36−4.33 ± 0.046−6.33 ± 0.066−4.55 ± 0.108Formoterol−7.33−5.32 ± 0.076−7.42 ± 0.076−5.58 ± 0.076ICI118551−7.20−6.69 ± 0.035−7.16 ± 0.046−6.35 ± 0.036ICI215001−5.79−5.40 ± 0.066−5.68 ± 0.056−4.96 ± 0.077Isoprenaline−6.86−5.13 ± 0.057−6.67 ± 0.137−5.16 ± 0.057Labetolol−7.51−6.48 ± 0.035−7.49 ± 0.046−6.48 ± 0.076L755507−7.17−7.00 ± 0.066−7.40 ± 0.067−6.96 ± 0.076Metaproterenol−5.64−3.57 ± 0.036−5.71 ± 0.086−3.49 ± 0.085Metoprolol−6.42−5.68 ± 0.036−6.10 ± 0.057−5.27 ± 0.077Nadolol−7.99−7.33 ± 0.025−7.98 ± 0.036−7.08 ± 0.096Noradrenaline−6.60−4.40 ± 0.036−6.29 ± 0.057−4.53 ± 0.117Nebivolol−8.25−8.01 ± 0.014−8.35 ± 0.056−7.73 ± 0.096Pindolol−8.55−7.92 ± 0.065−8.56 ± 0.066−8.01 ± 0.056Pronethalol−6.85−6.11 ± 0.035−6.93 ± 0.046−6.12 ± 0.086Propranolol−8.51−7.92 ± 0.056−8.59 ± 0.057−7.78 ± 0.077Ractopamine−6.75−5.82 ± 0.066−6.85 ± 0.036−5.71 ± 0.106Salbutamol−4.99−4.16 ± 0.066−5.35 ± 0.066−4.20 ± 0.076Salmeterol−5.92−5.31 ± 0.057−6.36 ± 0.088−5.51 ± 0.066SDZ21009−9.27−8.57 ± 0.065−9.41 ± 0.046−8.62 ± 0.086SR59230A−7.39−7.10 ± 0.056−7.81 ± 0.067−7.50 ± 0.107Sotalol−6.14−5.47 ± 0.035−6.06 ± 0.056−5.21 ± 0.056Terbutaline−4.61≥33−5.07 ± 0.086≥35Timolol−8.76−7.95 ± 0.035−8.90 ± 0.045−7.82 ± 0.056Tulobuterol−5.60−4.82 ± 0.035−5.69 ± 0.087−5.00 ± 0.106Xamoterol−6.58−5.42 ± 0.036−6.60 ± 0.056−5.27 ± 0.096ZD2079−3.77≥44−4.15 ± 0.073≥46ZD7114−7.30−6.55 ± 0.045−7.07 ± 0.046−6.28 ± 0.086Zinterol−6.40−5.42 ± 0.056−6.52 ± 0.066−5.40 ± 0.066Values represent mean ± SEM for *n* separate experiments^a^The tβtrunc data is taken from Baker ([@CR5])Fig. 2Inhibition of ^3^H-CGP12177 specific binding to whole cells by **a** the antagonist timolol and **b** the agonist isoprenaline at each of the turkey β-adrenoceptors mutants. Nonspecific binding was determined by 10 μM propranolol. The concentration of 3H-CGP 12177 present in these experiments was 1.6 nM. Data points are mean ± SE mean of triplicate determinations. These single experiments are representative of **a** five and **b** seven separate experiments

Agonist efficacy---^3^H-cAMP accumulation and CRE-SPAP production {#Sec14}
-----------------------------------------------------------------

The agonist response to 24 ligands (seven-point concentration--response curves) was examined for each of the turkey β-adrenoceptor mutants (Table [2](#Tab2){ref-type="table"}). A further 24 ligands were examined at maximum concentrations only (Table [3](#Tab3){ref-type="table"}). This enabled ligands to be classified into full agonists (those ligands that stimulated a greater than 85% maximum response to isoprenaline in the cAMP assays at the tβtrunc receptor), partial agonists (those that stimulated between 10--85% maximum responses at the tβtrunc receptor) and antagonists (those ligands that stimulated less than 10% maximum response at the tβtrunc receptor). This allowed the study of ligand affinity to be further examined to assess whether a particular subset of ligands (e.g. agonists) were disproportionately affected by the mutations (Fig. [3](#Fig3){ref-type="fig"}). Table 2Log EC~50~ values and % isoprenaline maximal responses obtained from ^3^H-cAMP accumulation assays in CHO tβtrunc cells, β6--m23 cells, β36 cells and β36--m23 cellstβtrunc bindingβ6--m23β36β36--m23Log EC~50~ cAMP% isop max*n*Log EC~50~ cAMP% isop max*n*Log EC~50~ cAMP% isop max*n*Log EC~50~ cAMP% isop max*n*Fenoterol−7.95 ± 0.08114 ± 56−5.80 ± 0.0981 ± 77−6.91 ± 0.02117 ± 26100 μM7.4 ± 1.43Cimaterol−8.67 ± 0.10114 ± 46−7.01 ± 0.0682 ± 86−7.77 ± 0.06108 ± 26−6.23 ± 0.1811 ± 27Ractopamine−7.87 ± 0.08114 ± 53−6.66 ± 0.0842 ± 54−7.22 ± 0.0557 ± 43100 μMNo response3Dobutamine−6.73 ± 0.09112 ± 75−6.02 ± 0.0230 ± 45−6.13 ± 0.0488 ± 34100 μMNo response3Adrenaline−7.16 ± 0.11110 ± 25−5.63 ± 0.08105 ± 45−6.29 ± 0.07116 ± 45−4.44 ± 0.0247 ± 35Formoterol−8.85 ± 0.06108 ± 65−7.50 ± 0.1297 ± 25−7.92 ± 0.03106 ± 4510 μM34 ± 23Noradrenaline−7.89 ± 0.05107 ± 55−6.16 ± 0.0696 ± 25−6.92 ± 0.09119 ± 66−4.99 ± 0.0250 ± 45Zinterol−7.64 ± 0.05101 ± 13−6.40 ± 0.0466 ± 23−6.88 ± 0.0362 ± 3310 μMNo response3Isoprenaline−8.40 ± 0.0810013−7.23 ± 0.0710013−7.53 ± 0.1010014−5.85 ± 0.0510014BRL37344−6.32 ± 0.1197 ± 33−5.10 ± 0.1260 ± 84−5.48 ± 0.0553 ± 53100 μMNo response3Salbutamol−6.12 ± 0.0697 ± 24−4.79 ± 0.0235 ± 64−5.41 ± 0.0238 ± 34100 μMNo response3Salmeterol−7.05 ± 0.0291 ± 23−5.59 ± 0.0725 ± 93−6.34 ± 0.0638 ± 5310 μMNo response3Clenbuterol−7.63 ± 0.0986 ± 45−6.47 ± 0.1041 ± 75−7.10 ± 0.0524 ± 25100 μMNo response4Tulobuterol−6.40 ± 0.0878 ± 65−5.40 ± 0.1313 ± 24−5.79 ± 0.0718 ± 24100 μMNo response3ZD7114−7.80 ± 0.0976 ± 13−7.03 ± 0.046.1 ± 0.73−7.42 ± 0.1034 ± 57100 μMNo response3Xamoterol−7.22 ± 0.0861 ± 74−5.76 ± 0.178.3 ± 1.54−6.94 ± 0.0913 ± 14100 μMNo response3Denopamine−6.81 ± 0.0245 ± 3410 μM11 ± 26−6.64 ± 0.096.5 ± 0.3410 μMNo response3CGP20712A−8.21 ± 0.196.3 ± 0.75−7.31 ± 0.162.7 ± 0.74100 μMNo response3100 μMNo response3Propranolol−8.53 ± 0.146.1 ± 1.45100 μMNo response6−8.11 ± 0.443.3 ± 1.05100 μMNo response3BisoprololNo response3−6.63 ± 0.390.4 ± 0.14100 μMNo response3100 μMNo response3ICI118551No response3100 μMNo response4100 μMNo response3100 μMNo response3Values are mean ± SEM of *n* separate determinationsTable 3% isoprenaline maximal responses obtained from ^3^H-cAMP accumulation assays in CHO tβtrunc cells, β6--m23 cells, β36 cells and β36--m23 cells, in response to a maximum concentration of ligandtβtrunc*n*β6--m23β36*n*β36--m23*n*Concentration used% isop max% isop max% isop max% isop maxMetaproterenol100 μM124 ± 6492 ± 34141 ± 646.1 ± 0.34Terbutaline1 mM120 ± 3475 ± 34100 ± 442.3 ± 0.34BRL35135A10 μM99 ± 3481 ± 4480 ± 6412 ± 14ICI21500110 μM75 ± 3410 ± 1433 ± 34No response4ZD2079100 μM73 ± 9425 ± 2438 ± 240.4 ± 0.14L75550710 μM59 ± 845 ± 0.3410 ± 14No response4Bucindolol10 μM49 ± 1417 ± 1412 ± 14No response4SR59230A1 μM38 ± 241.4 ± 0.144.9 ± 0.74No response4Pindolol10 μM31 ± 141.5 ± 0.143.4 ± 0.84No response4Alprenolol10 μM31 ± 241.3 ± 0.344.9 ± 0.84No response4Acebutolol100 μM30 ± 141.2 ± 0.246.7 ± 0.44No response4Labetolol100 μM29 ± 146.1 ± 0.643.5 ± 0.64No response4Pronethalol100 μM29 ± 144.8 ± 0.342.4 ± 0.74No response4SDZ2100910 μM24 ± 144.4 ± 0.243.7 ± 0.34No response4Carvedilol10 μM12 ± 0.440.6 ± 0.14No response4No response4Butoxamine100 μM7.1 ± 0.14No responseNo response4No response4Bupranolol10 μM4.4 ± 0.24No response4No response4No response4Timolol10 μM5.0 ± 0.340.4 ± 0.083No response4No response4Nadolol10 μM2.6 ± 0.34No response4No response4No response4Atenolol100 μM2.1 ± 14No response4No response4No response4Betaxolol100 μM1.7 ± 0.440.5 ± 0.14No response4No response4Nebivolol10 μM1.2 ± 0.34No response4No response4No response4Metoprolol100 μMNo response4No response4No response4No response4Sotalol100 μMNo response4No response4No response4No response4Values are mean ± SEM of *n* separate determinationsFig. 3Correlation plots of the log *K*~*D*~ values from ^3^H-CGP12177 whole cell binding for the turkey β-adrenoceptor mutants compared with each other. Ligands are shown as either full agonists (*filled circles*), partial agonists (*asterisks*) or antagonists (*open circles*). Categorisation into these classes was performed from data in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}, where ligands are defined as agonists if they stimulated more than 85% of the response at the human β1-adrenoceptor, as partial agonists if they stimulated 10--85% of the full response and as antagonists if they stimulated less than 10% of a full agonist response at the tβtrunc receptor

Initially, the ligands were incubated for 30 min with each cell line; however, as many responses were found to be very small, the response window was increased by extending the incubation time to 5 h. This does not affect the position (EC~50~ value) or maximum response of the concentration response curve in relation to isoprenaline or forskolin for the ligands, it merely increases the size of the response window enabling small responses to be observed more accurately (Baker [@CR6]). For example, the response to isoprenaline at 30 min and 5 h in each lines was, respectively: tβtrunc, −8.30 ± 0.10 (*n* = 8) and −8.54 ± 0.13 (*n* = 5); β6--m23, −7.23 ± 0.09 (*n* = 8) and −7.22 ± 0.11 (*n* = 5); β36, −7.48 ± 0.14 (*n* = 8) and −7.59 ± 0.16 (*n* = 6); and β36--m23, −5.84 ± 0.02 (*n* = 8) and −5.88 ± 0.11 (*n* = 6). The numbers given in Table [2](#Tab2){ref-type="table"} are therefore a mean of all the 30-min and 5-h data.

Direct comparison of data between cell lines is not possible (even in these CHO cells) because levels of receptor expression vary and the coupling of receptors to effectors may also differ between the different cell lines. Nevertheless, the rank order for the efficacy of ligands can be established by listing the ligands by the percentage of the maximum isoprenaline response observed. This was felt to be more appropriate than using Furchgott's efficacy ratio method (Furchgott [@CR15]) as many of the ligands in this study stimulated partial agonist responses. Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} are thus the response to agonist ligands presented in rank order of maximum response to isoprenaline as seen in the tβtrunc receptor cell line. Although there appear to be a few exceptions to the rank order using this method, they are generally in the ligands stimulating full agonist responses (e.g. dobutamine and ractopamine which have been shown to exhibit similar efficacy to BRL37344 and salbutamol at other β-adrenoceptors; Baker [@CR6]) and probably reflects the order in which the full agonists are presented. Generally, however the rank order of ligands, particularly once partial agonism is considered, is similar between tβtrunc and the mutant receptors, with the m23 mutations and β36 deletions causing a decrease in the amount of agonism seen and the β36--m23 receptor being the most severely affected (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). Fig. 4^3^H-cAMP accumulation in response to noradrenaline, adrenaline, clenbuterol and xamoterol in **a** tβtrunc cells, **b** β6--m23 cells, **c** β36 cells and **d** β36--m23 cells expressed as a percentage of the maximal response to isoprenaline in each experiment. Data points are mean ± SE mean of triplicate determinations. Each experiment is representative of **a** four, **b** four, **c** four and **d** three separate experiments

As the cell lines were all constructed from the same parent cell line, assessing the response to forskolin (which directly stimulates adenylyl cyclase thereby being independent of the level of receptor expression and receptor--effector coupling and should therefore be constant in all lines) and comparing this to isoprenaline in each line might give information about receptor--effector coupling. For example, for equal receptor--effector coupling, a line with very high receptor expression would be expected to have a larger response (compared with forskolin) and left-shifted EC~50~ value for the agonist.

The response to 10 μM forskolin was similar across all four cell lines (40.1 ± 3.9-fold over basal for tβtrunc; 37.8 ± 2.0-fold over basal for β36; 37.6 ± 2.2-fold over basal for β6--m23 and 40.7 ± 3.9-fold over basal for β36--m23 cell line). Interestingly, the β6--m23 cell line has a significantly higher receptor expression level than the other three cell lines and generated responses to isoprenaline that were far greater than the maximum response to forskolin (isoprenaline maximum was 197.8 ± 10.5% of the forskolin response, *n* = 8). The other cell lines generated lower total amounts of ^3^H-cAMP in response to isoprenaline relative to the forskolin response in each line, in keeping with their lower receptor expression levels (tβtrunc isoprenaline response was 35.9 ± 4.5% forskolin, *n* = 5; β36 cell line isoprenaline response was 85.3 ± 4.3 % of forskolin, *n* = 6; and the β36--m23 cell line isoprenaline response was 107.4 ± 14.6% of the forskolin response, *n* = 6). Thus, despite having a lot more receptor available and being able to stimulate a maximum response far in excess of that in the tβtrunc line, the concentration of isoprenaline required to stimulate a response was significantly greater in the β6--m23 cells than in the tβtrunc cells (log EC~50~ −8.40 in tβtrunc cells vs. −7.23 in β6--m23 cells). This suggests that the m23 mutations reduce the receptor's ability to generate a response either by reduced affinity, reduced ability to become activated or reduced receptor--effector coupling.

Isoprenaline stimulated CRE-SPAP gene transcription responses were 2.3- (Baker [@CR5]), 2.6 ± 0.01 (*n* = 21)-, 4.2 ± 0.2 (*n* = 6)- and 2.7 ± 0.10 (*n* = 10)-fold over basal for tβtrunc, β6--m23, β36 and β36--m23 receptors respectively (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}). Once again (better seen in Table [8](#Tab8){ref-type="table"} where partial agonists were examined), the m23 mutations and β36 deletions generated lower agonist responses than the tβtrunc cell line and the β36--m23 mutant was the most severely affected; however, the rank order of agonist efficacy remained largely undisturbed. Table 4Log EC~50~ values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO tβtrunc cellstβtrunc^a^Log EC~50~% isop max*n*Log *K*~*D*~ propranolol*n*Log *K*~*D*~ CGP20712ALog *K*~*D*~ ICI118551*n*Log *K*~*D*~ CGP12177*n*Fenoterol−8.17 ± 0.02120 ± 53−8.84 ± 0.059−8.20 ± 0.004−7.43 ± 0.055−9.66 ± 0.099Formoterol−8.96 ± 0.04115 ± 55−8.77 ± 0.0310−8.20 ± 0.105−7.44 ± 0.096−9.65 ± 0.078BRL37344−6.45 ± 0.05108 ± 48−8.72 ± 0.056−8.04 ± 0.0775−7.25 ± 0.088−9.44 ± 0.1111Cimaterol−8.63 ± 0.05122 ± 57−8.70 ± 0.059−8.24 ± 0.095−7.49 ± 0.046−9.54 ± 0.0714Clenbuterol−7.66 ± 0.05102 ± 412−8.52 ± 0.0516−7.82 ± 0.0913−7.32 ± 0.1012−9.40 ± 0.0715Salmeterol−6.86 ± 0.05112 ± 313−8.42 ± 0.0810−7.71 ± 0.0811−7.15 ± 0.109−9.32 ± 0.109Salbutamol−6.33 ± 0.07105 ± 410−8.41 ± 0.1010−7.93 ± 0.096−7.19 ± 0.086−9.34 ± 0.1110Adrenaline−7.13 ± 0.08117 ± 38−8.38 ± 0.1213−7.35 ± 0.129−6.82 ± 0.057−9.19 ± 0.068Noradrenaline−7.74 ± 0.04113 ± 412−8.35 ± 0.0716−7.51 ± 0.0811−6.98 ± 0.0713−9.05 ± 0.1011Isoprenaline−8.11 ± 0.1210010−8.21 ± 0.1018−7.25 ± 0.138−6.72 ± 0.1210−9.19 ± 0.1112Dobutamine−6.53 ± 0.06124 ± 53−8.19 ± 0.119−7.53 ± 0.095−6.80 ± 0.094−8.94 ± 0.087CGP12177−8.38 ± 0.0853 ± 420−7.23 ± 0.1218−6.91 ± 0.1512−6.36 ± 0.1711Log *K*~*D*~ values for propranolol, CGP20712, ICI118551 and CGP12177 as antagonists of the agonist responses are also given. Values are mean ± SEM of *n* separate determinations^a^Data table from Baker [@CR5]Table 5Log EC~50~ values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO β6--m23 cellsβ6--m23Log EC~50~% isop max*n*Log *K*~*D*~ propranolol*n*Log *K*~*D*~ CGP20712ALog *K*~*D*~ ICI118551*n*Log *K*~*D*~ CGP12177*n*Fenoterol−6.10 ± 0.0692 ± 212−8.33 ± 0.069−7.25 ± 0.069−7.03 ± 0.043−9.32 ± 0.074Formoterol−7.69 ± 0.08107 ± 218−8.24 ± 0.0213−7.19 ± 0.0710−6.97 ± 0.044−9.03 ± 0.118BRL37344−5.37 ± 0.0784 ± 212−8.43 ± 0.067−7.30 ± 0.056−7.14 ± 0.073−9.18 ± 0.073Cimaterol−7.25 ± 0.1596 ± 221−8.29 ± 0.0413−7.34 ± 0.077−6.99 ± 0.034−9.13 ± 0.0511Clenbuterol−6.69 ± 0.0477 ± 319−8.14 ± 0.0811−7.28 ± 0.148−7.10 ± 0.043−8.88 ± 0.077Adrenaline−5.81 ± 0.0897 ± 214−8.03 ± 0.0414−7.11 ± 0.083−6.76 ± 0.085−8.71 ± 0.097Noradrenaline−6.27 ± 0.1098 ± 315−7.72 ± 0.0514−6.87 ± 0.085−6.54 ± 0.095−8.61 ± 0.137Isoprenaline−7.39 ± 0.1110021−7.63 ± 0.1013−6.74 ± 0.137−6.55 ± 0.144−8.84 ± 0.225Dobutamine−5.90 ± 0.0655 ± 610−7.94 ± 0.064−6.62 ± 0.111−6.71 ± 0.044CGP12177−6.81 ± 0.0620 ± 215−6.03 ± 0.116−6.42 ± 0.204−5.39 ± 0.166Log *K*~*D*~ values for propranolol, CGP20712, ICI118551 and CGP12177 as antagonists of the agonist responses are also given. Values are mean ± SEM of *n* separate determinationsTable 6Log EC~50~ values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO β36 cellsβ36Log EC~50~% isop max*n*Log *K*~*D*~ propranolol*n*Log *K*~*D*~ CGP20712ALog *K*~*D*~ ICI118551*n*Log *K*~*D*~ CGP12177*n*Fenoterol−7.88 ± 0.0391 ± 53−8.69 ± 0.049−7.72 ± 0.164−7.45 ± 0.075−9.27 ± 0.079Formoterol−8.66 ± 0.0690 ± 34−8.54 ± 0.0510−8.10 ± 0.065−7.38 ± 0.126−9.20 ± 0.049BRL37344−6.21 ± 0.0290 ± 53−8.74 ± 0.046−8.03 ± 0.093−7.41 ± 0.054−9.35 ± 0.068Cimaterol−8.51 ± 0.0287 ± 36−8.71 ± 0.0310−7.90 ± 0.095−7.29 ± 0.046−9.24 ± 0.0513Clenbuterol−7.27 ± 0.0372 ± 36−8.48 ± 0.0316−7.72 ± 0.078−7.22 ± 0.077−8.96 ± 0.0810Adrenaline−6.72 ± 0.0895 ± 36−7.99 ± 0.1013−6.89 ± 0.177−6.77 ± 0.098−8.97 ± 0.0910Noradrenaline−7.43 ± 0.05102 ± 47−8.00 ± 0.0517−7.25 ± 0.097−6.89 ± 0.099−8.83 ± 0.0710Isoprenaline−7.80 ± 0.111006−8.04 ± 0.1114−6.94 ± 0.247−6.87 ± 0.128−8.73 ± 0.159Dobutamine−6.35 ± 0.02102 ± 33−8.21 ± 0.069−7.33 ± 0.055−6.88 ± 0.064−8.69 ± 0.077CGP12177−7.74 ± 0.1115 ± 110−6.95 ± 0.1212−6.23 ± 0.128−6.32 ± 0.178Log *K*~*D*~ values for propranolol, CGP20712, ICI118551 and CGP12177 as antagonists of the agonist responses are also given. Values are mean ± SEM of *n* separate determinationsTable 7Log EC~50~ values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO β36--m23 cellsβ36--m23Log EC~50~% isop max*n*Log *K*~*D*~ propranolol*n*Log *K*~*D*~ CGP20712ALog *K*~*D*~ ICI118551*n*Log *K*~*D*~ CGP12177*n*Fenoterol100 μM18 ± 25Formoterol−5.97 ± 0.0590 ± 44−7.95 ± 0.003−6.95 ± 0.064−6.74 ± 0.164−8.94 ± 0.034BRL37344No response3Cimaterol10 μM32 ± 38ClenbuterolNo response3Adrenaline−4.67 ± 0.0376 ± 36−7.94 ± 0.1010−6.87 ± 0.213−6.69 ± 0.124Noradrenaline−5.20 ± 0.0475 ± 29−6.85 ± 0.089−6.78 ± 0.089−9.10 ± 0.116Isoprenaline−6.20 ± 0.0210010−8.02 ± 0.0418−6.66 ± 0.0416−6.64 ± 0.0317−9.05 ± 0.0320DobutamineNo response3CGP12177No response11Log *K*~*D*~ values for propranolol, CGP20712, ICI118551 and CGP12177 as antagonists of the agonist responses are also given. Values are mean ± SEM of *n* separate determinations. For fenoterol and cimaterol, the response at the maximum concentration of 100 and 10 μM respectively is given as the top of the concentration response curve at these concentrations had not been reachedTable 8Log EC~50~ values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO tβtrunc, β6--m23, β36 and β36--m23 ce0llstβtruncβ6--m23β36β36--m23Log EC~50~% isop max*n*Log EC~50~% isop max*n*Log EC~50~% isop max*n*Log EC~50~% isop max*n*Salmeterol−6.86 ± 0.05112 ± 313−5.75 ± 0.0561 ± 413−6.57 ± 0.0274 ± 38No response05Terbutaline−6.09 ± 0.08106 ± 43−4.61 ± 0.0861 ± 86−5.89 ± 0.0378 ± 0.33No response03Salbutamol−6.33 ± 0.07105 ± 410−4.99 ± 0.0450 ± 212−5.89 ± 0.0464 ± 63No response03Tulobuterol−6.48 ± 0.0877 ± 103−5.13 ± 0.0429 ± 57−6.08 ± 0.0358 ± 33No response03ZD7114−7.82 ± 0.1263 ± 33−7.15 ± 0.0415 ± 33−7.40 ± 0.0856 ± 53No response03Xamoterol−7.26 ± 0.0768 ± 13−5.77 ± 0.1221 ± 93−6.96 ± 0.1351 ± 53No response03Denopamine−6.70 ± 0.0758 ± 3510 μM10 ± 34−6.29 ± 0.1440 ± 24No response03Labetolol−7.58 ± 0.1935 ± 53−6.56 ± 0.0413 ± 24−7.48 ± 0.039.6 ± 0.53No response03S-Cyanopindolol−10.22 ± 0.1634 ± 57−7.96 ± 0.3116 ± 33−9.62 ± 0.096.5 ± 0.63No response03Pronethalol−7.23 ± 0.1627 ± 23No response03No responseNo response03Carazolol−8.34 ± 0.3425 ± 37No response03No responseNo response03For denopamine in β6--m23 cells, the response at the maximum concentration of 10mM is given as the top of the concentration response curve had not been reached by this maximum concentration. Values are mean ± SEM of *n* separate determinations

Evidence for two agonist-induced conformations---^3^H-cAMP accumulation and CRE-SPAP production {#Sec15}
-----------------------------------------------------------------------------------------------

Next, the β36 deletions and the m23 mutations were each examined separately to determine the effects of these mutations on the two agonist-induced conformations of the tβtrunc receptor. Several agonists stimulated CRE-SPAP responses that were inhibited by propranolol, CGP20712A and ICI118551 (Fig. [5](#Fig5){ref-type="fig"}, Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}) in a competitive manner. CGP12177 also acted as an antagonist, inhibiting both of these mutant receptor responses with high affinity (Fig. [6](#Fig6){ref-type="fig"}, Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}). Also, CGP12177 itself stimulated a partial agonist response at both of these mutants and in each case the log EC~50~ value was significantly higher than the *K*~*D*~ value for CGP12177 at the mutant receptor (Fig. [7](#Fig7){ref-type="fig"}, Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}). In addition, these CGP12177 agonist responses required significantly higher concentrations of propranolol, CGP20712A and ICI118551 to be inhibited than the other agonists (Fig. [7](#Fig7){ref-type="fig"}, Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}). This is in keeping with two agonist-induced conformations (a catecholamine site conformation and a secondary CGP12177 site conformation) on each of the β36 and β6--m23 receptor mutants. Fig. 5CRE-SPAP production in response to clenbuterol in the absence and presence of propranolol in **a** tβtrunc cells, **b** β6--m23 cells, **c** β36 cells and **d** β36--m23 cells. *Bars* represent basal CRE-SPAP production, that in response to 10 μM isoprenaline and that in response 10, 100, 1,000 or 30, 300, 3,000 nM propranolol alone. Data points are mean ± SEM of triplicate determinations. The Schild slopes for each experiment are **a** 0.95, **b** 0.98 and **c** 1.00. Each experiment is representative of **a** five, **b** five, **c** five, and **d** three separate experimentsFig. 6CRE-SPAP production in response to cimaterol in **a** β6--m23 and **b** β36 cells in the absence and presence of CGP12177. *Bars* represent basal CRE-SPAP production that in response to 10 μM isoprenaline and that in response 1, 10, 30 or 100 nM CGP12177 alone. Data points are mean ± SEM of triplicate determinations. Each experiment is representative of **a** five and **b** five separate experimentsFig. 7CRE-SPAP production in response to CGP12177 in **a** β6--m23 and **b** β36 cells in the absence and presence of propranolol. *Bars* represent basal CRE-SPAP production, that in response to 10 μM isoprenaline and that in response 1, 10 or 100 μM propranolol alone. Data points are mean ± SEM of triplicate determinations. Each experiment is representative of **a** five and **b** five separate experiments

When these mutations were combined in the β36--m23 mutant receptor, many agonists did not stimulate any response (Fig. [5d](#Fig5){ref-type="fig"}, Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}). In addition, CGP12177 itself did not stimulate any agonist response at the β36--m23 receptor making it difficult to determine whether this mutant does indeed have two agonist-induced conformations. However, responses were seen to a few agonists and these responses were inhibited by classical antagonists in a competitive manner (propranolol, ICI118551 and CGP20712A, Fig. [8a](#Fig8){ref-type="fig"}, Table [7](#Tab7){ref-type="table"}). In addition, CGP12177 also inhibited these agonist responses with high affinity in a similar manner to the original tβtrunc receptor (Fig. [8b](#Fig8){ref-type="fig"}, Table [7](#Tab7){ref-type="table"}). Fig. 8CRE-SPAP production in response to isoprenaline in β36--m23 cells in the absence and presence of **a** propranolol and **b** CGP12177. *Bars* represent basal CRE-SPAP production, that in response to 10 μM isoprenaline and that in response 10, 100 1,000 nM propranolol or 1, 10 or 100 nM CGP12177 alone. Data points are mean ± SEM of triplicate determinations. Each experiment is representative of **a** seven and **b** seven separate experiments. The Schild slopes for each experiment are **a** 1.00 and **b** 1.05

Further evidence for two sites or conformations was also sought by using the ^3^H-cAMP accumulation assay, which has the largest response window, thus making the detailed examination of agonist responses possible. S-Cyanopindolol was the ligand bound to the β36--m23 receptor from which the X-ray structure was determined (Warne et al. [@CR29]) and it stimulated an ^3^H-cAMP accumulation response that was best described by a two-component response curve (Fig. [9a](#Fig9){ref-type="fig"}). CGP12177 and carazolol similarly stimulated two-component response curves (Table [9](#Tab9){ref-type="table"}). Two component response curves were also seen for β6--m23 and β36 receptors (Fig. [9b and c](#Fig9){ref-type="fig"}, Table [9](#Tab9){ref-type="table"}). No responses to cyanopindolol, carazolol or CGP12177 were seen for the β36--m23 receptor (Fig. [9d](#Fig9){ref-type="fig"}). Fig. 9^3^H-cAMP accumulation in response to cyanopindolol in **a** tβtrunc cells, **b** β6--m23 cells, **c** β36 cells and **d** β36--m23 cells. Bars represent basal ^3^H-cAMP accumulation and that in response to 10 μM isoprenaline. Data points are mean ± SE mean of triplicate determinations. Each experiment is representative of **a** four, **b** 12, **c** six and **d** three separate experimentsTable 9Log EC~50~ values and % isoprenaline maximal responses obtained in response to S-cyanopindolol, carazolol and CGP 12177 from ^3^H-cAMP accumulation responses in CHO tβtrunc, β6--m23, β36 and β36--m23 cellsLigandreceptorLog EC~50~ 1Log EC~50~ 2% site 1% isoprenaline max*n*S-Cyanopindololtβtrunc−10.72 ± 0.06−7.84 ± 0.1367 ± 139 ± 14β6--m23−9.24 ± 0.06−6.88 ± 0.1144 ± 29.2 ± 1.012β36−10.42 ± 0.36−7.46 ± 0.3666 ± 57.4 ± 4.96β36--m23No response3Carazololtβtrunc−9.96 ± 0.06−6.70 ± 0.0843 ± 221 ± 18β6--m23−8.69 ± 0.24−6.14 ± 0.1825 ± 32.5 ± 0.28β36−9.92 ± 0.52−6.52 ± 0.2143 ± 103.4 ± 0.55β36--m23No response3CGP 12177tβtrunc−9.18 ± 0.03−6.73 ± 0.1756 ± 351 ± 34β6--m23−7.96 ± 0.11−5.94 ± 0.1535 ± 211 ± 211β36−9.26 ± 0.15−6.78 ± 0.1554 ± 511 ± 56β36--m23No response9Where the response is best described by a two-component response, the log EC~50~ 1 and log EC~50~ 2 are given along with the % of the response occurring at site 1. Values are mean ± SEM of *n* separate determinations

Finally, at the original tβtrunc receptor, the stimulatory responses to cimaterol were inhibited by low concentrations of CGP12177, with higher concentrations of CGP12177 causing the CGP12177 agonist response (Fig. [10a](#Fig10){ref-type="fig"}). This pattern, which can only be explained by two agonist sites or conformations (Baker [@CR5]), was also seen at the β6--m23 and β36 mutant receptors (Fig. [10b, c](#Fig10){ref-type="fig"}). Similar patterns were also seen with isoprenaline, clenbuterol and formoterol as agonists. Only the inhibition of the agonist responses to isoprenaline, cimaterol and formoterol were seen at the β36--m23 receptor (Fig. [10d](#Fig10){ref-type="fig"}). Fig. 10^3^H-cAMP accumulation in response to CGP12177 in **a** tβtrunc cells, **b** β6--m23 cells, **c** β36 cells and **d** β36--m23 cells in the absence and presence of cimaterol. *Bars* represent basal ^3^H-cAMP accumulation, that in response to 10 μM isoprenaline and that in response to 3, 10, 30, 100, 300 or 1,000 nM cimaterol. Data points are mean ± SE mean of triplicate determinations. Each experiment is representative of **a** four, **b** six, **c** six and **d** four separate experiments

Parent CHO cells {#Sec16}
----------------

There was no specific binding of ^3^H-CGP12177 to the parent CHO cells (i.e. CHO cells without a transfected receptor). In addition, in the ^3^H-cAMP accumulation cAMP assay and the CRE-SPAP gene transcription assay, the parent CHO cells responded to forskolin but no responses were seen to any of the other ligands used in this study (Baker [@CR5]).

Discussion {#Sec17}
==========

Effect of the β36 deletions and m23 mutations on ligand affinity {#Sec18}
----------------------------------------------------------------

The X-ray crystal structure of the turkey β-adrenoceptor was recently determined but several mutations were required to stabilise the protein before the crystallisation process could occur (Warne et al. [@CR29], [@CR30]). To realise the full potential of this structure, it is important to understand the extent to which these mutations affects the pharmacology. Firstly, ligand affinity was examined. The β36 deletions made no difference to the ability of ligands to bind (compared to the tβtrunc construct). This was true for agonists, partial agonists and neutral antagonists. In the correlation plot (Fig. [3b](#Fig3){ref-type="fig"}), the ligands are clearly seen to have the same affinity for both the tβtrunc and β36 receptor and the line of best-fit passes through the origin. This is consistent with the view that the N-terminus, C-terminus and most of cytoplasmic loop 3 do not interact directly or indirectly with the ligand-binding pocket.

The m23-thermostabilising mutations resulted in a lower affinity for all ligands--agonists, partial agonists or neutral antagonists. The line of best fit (Fig. [3a, c](#Fig3){ref-type="fig"}) does not pass through the origin for either β6--m23 or β36--m23 receptors because all the ligands have about tenfold lower affinity. Interestingly, several of the most efficacious agonists (e.g. fenoterol, cimaterol, adrenaline, formoterol, noradrenaline and isoprenaline) have a greater than tenfold reduction in affinity with the m23 mutations, but this is not uniform across all agonists.

Previous ligand binding data for β6--m23 (Serrano-Vega et al. [@CR24]) showed that cyanopindolol and dihydroalprenolol bound to the thermostabilised receptor with similar affinities to the unmutated receptor, whereas the binding of the agonists isoprenaline and noradrenaline was weaker by 650- and 2,470-fold, respectively. The significant difference between these results and the results presented here is most likely related to the environment in which these assays were performed. The binding experiments of Serrano-Vega et al. ([@CR24]) were performed on *Escherichia coli-*expressed receptors after solubilisation in the detergent dodecylmaltoside, whereas the binding experiments performed here were in living mammalian whole cells.

Effect of the β36 deletions and m23 mutations on ligand efficacy and receptor activation {#Sec19}
----------------------------------------------------------------------------------------

Next, the effect on ligand efficacy (or ability for receptor activation) was investigated. As agonist efficacy depends on many factors, including the level of receptor expression (Clarke and Bond [@CR12]; Kenakin [@CR18], [@CR19]), it is difficult to directly compare across cell lines. However, in both functional assays, the catecholamines isoprenaline, adrenaline and noradrenaline were able to stimulate agonist response via all four receptors, including β36--m23 although much higher concentrations of agonist were required to achieve this.

As ligand affinity is reduced in the β6--m23 and β36--m23 mutants, all other things being equal, higher concentrations of agonist would be expected to be required to stimulate a response compared to the tβtrunc or β36 mutant. This was indeed observed, even in the β6--m23 line with its higher receptor expression level. Looking further at the other agonist ligands, with a range of efficacies from full to weak partial agonists (e.g. Tables [3](#Tab3){ref-type="table"} and [8](#Tab8){ref-type="table"}), progressively fewer ligands were able to stimulate agonist responses via the β36 and β6--m23 mutants alone. For the β6--m23 receptor, the reduced ability of the receptor to activate a response, whilst partly being due to the reduction in affinity, is also consistent with the theory that the m23 mutations increase the stability of the receptor and thus increase the energy barrier required for receptor activation. However, as the β36 deletions did not affect ligand affinity, the reduced ability of the β36 mutant to activate responses may be a direct effect of the mutations reducing the receptor--G-protein interaction, consistent with extensive data implicating cytoplasmic loop 3 and the C-terminus of GPCRs in the receptor--G-protein activation process.

When the two were combined, the effect was even more striking with very few agonists being able to elicit a response from the β36--m23 mutant.

The effect of the β36 deletions and m23 mutations on the two agonist-induced conformations {#Sec20}
------------------------------------------------------------------------------------------

The human β~1~-adrenoceptor and the tβtrunc exist in two pharmacologically active agonist-induced conformations, consisting of a high-affinity site where catecholamines stimulate responses and classical β-adrenoceptor antagonists bind with high affinity and a secondary site where CGP12177 stimulates an agonist response and classical antagonists have much higher affinity (Arch [@CR1]; Baker [@CR3], [@CR5]; Granneman [@CR16]; Kaumann and Molenaar [@CR17]; Konkar et al. [@CR20]; Lowe et al. [@CR21]; Molenaar [@CR22]). Thus, CGP12177 binds to the tβtrunc catecholamine site with high affinity (*K*~*D*~ 0.32 nM from ^3^H-CGP12177 binding and 0.22--1.5 nM from antagonism of agonist responses; Baker [@CR5]), but requires higher concentrations to stimulate agonist responses (EC~50~ 4.17 nM), suggesting that this CGP12177 agonist response is occurring via a secondary site (Baker [@CR5]). Furthermore, the concentrations of antagonists required to inhibit the CGP12177 response are significantly higher than those required to inhibit the other agonist responses (Baker [@CR5]).

In the β6--m23 and β36 mutants, CGP12177 bound with high affinity in both the binding assay and as an antagonist in the functional CRE-SPAP assay suggesting that CGP12177 binds with high affinity to the catecholamine site on both mutants. CGP12177 also stimulated agonist responses via both of these mutations but required a higher concentration (higher EC~50~ value) than expected from its *K*~*D*~ value at each receptor (β6--m23 *K*~*D*~ 0.85 nM on binding, *K*~*D*~ 0.48--1.45 nM on CRE-SPAP but EC~50~ of 155 nM on CRE-SPAP; β36 *K*~*D*~ 0.34 nM on binding, *K*~*D*~ 0.54--2.04 nM on CRE-SPAP but EC~50~ of 18.2 nM on CRE-SPAP). Also, the concentration of antagonists required to inhibit the CGP12177 agonist responses were significantly higher than those required to inhibit the other agonists. This suggests that the β6--m23 receptor and the β36 receptor both exist in at least two agonist-induced conformations. When both mutations are combined (β36--m23), CGP12177 was able to bind with high affinity and antagonise catecholamine responses with high affinity, suggesting that CGP12177 binds with high affinity catecholamine site on the receptor. However, CGP12177 itself did not simulate an agonist response via the β36--m23 receptor. This could be because either the ability of the β36--m23 receptor to stimulate responses is too poor to allow detection of partial agonist responses or because the combination of the β36 deletions and the m23 mutations has disrupted the secondary site on the turkey receptor.

Further evidence for two receptor conformations comes from ligands that stimulate two-component concentration response curves (Baker et al. [@CR7]; Walter et al. [@CR27])---examples at the tβtrunc receptor being CGP12177 itself, S-cyanopindolol and carazolol (Baker [@CR5]). CGP12177, carazolol and S-cyanopindolol all stimulated two-component agonist response curves via both the β6--m23 and β36 receptors. This again suggests that neither mutation cause a major disruption to the secondary site on the receptor. Once again, no response was seen in the combined β36--m23 mutant. Again this could be because the combination of mutations disrupted the secondary site or because the ability of this heavily mutated receptor to stimulate agonist responses is too reduced to be able to examine these partial agonists.

The final evidence for two receptor conformations comes from the inhibition of a catecholamine site agonist response by CGP12177 at lower concentrations than those required to stimulate the CGP12177 agonist response (Baker [@CR5]; Konkar et al. [@CR20]). When the β36 and β6--m23 mutants were examined alone, this was also the case. Thus CGP12177 at low concentrations inhibited, e.g. the cimaterol response (occurring via the catecholamine site), but higher concentrations of CGP12177 were required to stimulate a CGP12177 agonist response, occurring via the secondary site. This again suggests that both of these mutant receptors exist in two agonist-induced conformations. For the combined β36--m23 mutant, CGP12177 inhibited the cimaterol response with high affinity, consistent with it binding to the catecholamine site, but the lack of the stimulation in response to CGP12177 once again precluded the demonstration of the secondary site in the β36--m23 receptor.

Conclusion {#Sec21}
==========

This detailed pharmacological analysis of the effects of the β36 deletions and the m23 thermostabilising mutations alone, and in combination, shows that the final crystallised receptor (β36--m23), whilst having severely reduced ability to activate responses compared to the original tβtrunc receptor, is still a fully functional receptor, capable of binding agonist and antagonist ligands and activating intracellular agonist responses. The m23 mutations reduced affinity for agonists, partial agonists and neutral antagonists whilst the β36 deletions alone had no effect on ligand affinity. Both sets of changes appeared to reduce the agonist activation of the receptor---the β36 deletions most likely by reducing receptor--G-protein activation and the m23 mutations by both reducing ligand affinity and receptor activation (most likely by the increased receptor stability and thus an increased activation energy requirement). Finally, both the β6--m23 and the β36 receptors retained two active agonist-induced receptor conformations similar to that of the original tβtrunc receptor, although due to the severely reduced activation ability of the β36--m23 mutant receptor, this feature is difficult to assess in the final combined mutant.

Thus, the original contention that the β36--m23 receptor is preferentially in an antagonist-binding conformation appears to be more complex than previously anticipated, not least because only a proportion of the agonists tested showed a marked reduction in affinity compared to the antagonists. The pharmacological characterisation also suggests that the structure of β36--m23 with cyanopindolol bound may represent the receptor bound with a weak partial agonist. Finally, this work provides a solid foundation for the analysis of further structures of the mutated turkey β-adrenoceptor with different bound ligands.
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